What are the recommended dosing regimens for hydroxyurea for sickle cell disease, chronic myeloid leukemia, and essential thrombocythemia?

Hydroxyurea Dosing Recommendations

Sickle Cell Disease

For sickle cell disease, initiate hydroxyurea at 15-20 mg/kg/day and escalate to maximum tolerated dose (MTD) of 25-35 mg/kg/day for optimal clinical benefit. 1, 2

Initial Dosing Strategy

• Starting dose: 15 mg/kg once daily (FDA-approved) 1
• Dose escalation: Increase by 2.5-5.0 mg/kg every 8 weeks as tolerated 3
• Target MTD: 20-35 mg/kg/day, defined by mild myelosuppression 3

Evidence for Dose Escalation

The NOHARM MTD trial demonstrated that dose escalation to approximately 30 mg/kg/day was superior to fixed dosing at 20 mg/kg/day in sub-Saharan African children 2. The escalated dose group achieved:

• 86% reaching therapeutic targets (hemoglobin ≥9.0 g/dL or fetal hemoglobin ≥20%) versus 37% in fixed-dose group
• 57% reduction in vaso-occlusive crises (incidence rate ratio 0.43)
• 73% reduction in acute chest syndrome (incidence rate ratio 0.27)
• Equivalent safety profiles between groups

The REACH trial extended these findings over 8 years, showing sustained benefits with MTD dosing (mean 28.2 mg/kg/day) including 40% reduction in vaso-occlusive episodes and 79% reduction in acute chest syndrome compared to fixed dosing 3.

Alternative Low-Dose Approach

However, fixed low-dose hydroxyurea at 10-15 mg/kg/day remains a reasonable alternative in resource-limited settings or patients with baseline neutropenia. 4, 5

Studies from Oman and Brazil demonstrated that doses of 10-15 mg/kg/day produced significant clinical improvements with fewer hematologic toxicities 4, 5. This approach is particularly relevant for populations with ethnic neutropenia where myelosuppression risk is higher.

Renal Dose Adjustment

Reduce dose by 50% (to 7.5 mg/kg once daily) in patients with creatinine clearance <60 mL/min or end-stage renal disease. 1 On dialysis days, administer after hemodialysis.

Monitoring Requirements

• Weekly blood counts during dose escalation 1
• Monthly monitoring once stable dose achieved
• Correct severe anemia before initiating therapy 1
• Prophylactic folic acid supplementation recommended 1

---

Myeloproliferative Neoplasms

Polycythemia Vera (PV)

For high-risk PV requiring cytoreduction, initiate hydroxyurea at 2 g/day (2.5 g/day if body weight >80 kg) as first-line therapy. 6

Treatment goals:

• Maintain hematocrit <45% without phlebotomy 7
• Platelet count <400 × 10⁹/L
• WBC count <10 × 10⁹/L
• Resolution of disease-related symptoms

Resistance/intolerance criteria (indicating need for second-line therapy like ruxolitinib): 6, 7, 8, 9

1. Need for phlebotomy after 3 months of ≥2 g/day
2. Uncontrolled myeloproliferation (platelets >400 × 10⁹/L AND WBC >10 × 10⁹/L) after 3 months of ≥2 g/day
3. Failure to reduce massive splenomegaly by >50% after 3 months of ≥2 g/day
4. Cytopenias at lowest effective dose (ANC <1.0 × 10⁹/L OR platelets <100 × 10⁹/L OR hemoglobin <10 g/dL)
5. Unacceptable toxicities (leg ulcers, mucocutaneous manifestations, GI symptoms, pneumonitis, fever)

Important caveat: Use hydroxyurea with caution in patients <40 years old due to potential leukemogenic risk with long-term exposure 6.

Essential Thrombocythemia (ET)

For high-risk ET, initiate hydroxyurea at 2 g/day (2.5 g/day if body weight >80 kg). 6

Treatment goal:

• Platelet count <400 × 10⁹/L (optimal target in daily practice) 7

Resistance/intolerance criteria: 6, 7, 9

1. Platelet count >600 × 10⁹/L after 3 months of ≥2 g/day (2.5 g/day if >80 kg)
2. Platelet count >400 × 10⁹/L AND WBC <2.5 × 10⁹/L at any dose
3. Platelet count >400 × 10⁹/L AND hemoglobin <10 g/dL at any dose
4. Leg ulcers or mucocutaneous manifestations at any dose
5. Hydroxyurea-related fever

Primary Myelofibrosis (MF)

For MF-associated splenomegaly or thrombocytosis/leukocytosis, hydroxyurea at 2 g/day is first-line cytoreductive therapy. 10

However, ruxolitinib has largely supplanted hydroxyurea as preferred therapy for symptomatic MF with splenomegaly based on superior efficacy in the COMFORT trials 10. Hydroxyurea remains appropriate for:

• Low/intermediate-1 risk patients with isolated leukocytosis (WBC >25 × 10⁹/L) or thrombocytosis (platelets >1000 × 10⁹/L)
• Patients ineligible for or declining JAK inhibitor therapy

Resistance/intolerance criteria: 7

1. Failure to reduce massive splenomegaly by >50% after 3 months of ≥2 g/day
2. Uncontrolled myeloproliferation (platelets >400 × 10⁹/L AND WBC >10 × 10⁹/L) after 3 months of ≥2 g/day
3. Cytopenias at lowest effective dose (ANC <1.0 × 10⁹/L OR platelets <50 × 10⁹/L)
4. Unacceptable toxicities

---

Chronic Myeloid Leukemia (CML)

Hydroxyurea is indicated only for resistant CML where tyrosine kinase inhibitors have failed or are contraindicated. 1 Specific dosing for CML is not standardized in current guidelines, as TKIs are first-line therapy. When used, dosing should be individualized based on blood counts and clinical response, typically starting at 20-30 mg/kg/day.

---

Critical Safety Considerations

Contraindications

• Previous hypersensitivity to hydroxyurea 1
• Marked bone marrow depression 1

Key Warnings

• Myelosuppression: Most common toxicity; monitor weekly initially 1
• Carcinogenicity: Secondary leukemia and skin cancers reported with long-term use 1
• Teratogenicity: Contraception required for 6 months (females) to 1 year (males) after therapy 1
• Hemolytic anemia: Discontinue if confirmed hemolysis occurs 1

Drug Interactions

• Avoid combination with didanosine/stavudine in HIV patients due to fatal pancreatitis and hepatotoxicity risk 1
• Interferes with continuous glucose monitoring systems: May falsely elevate readings 1